These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors. Jeziorski M; White FJ Synapse; 1989; 4(4):267-80. PubMed ID: 2603146 [TBL] [Abstract][Full Text] [Related]
6. Regulation of dopaminergic activity, but not tyrosine hydroxylase, is diminished after chronic inorganic lead exposure. Lasley SM Neurotoxicology; 1992; 13(3):625-35. PubMed ID: 1361980 [TBL] [Abstract][Full Text] [Related]
7. Neurochemical correlates of behavioral sensitization following repeated apomorphine treatment: assessment of the role of D1 dopamine receptor stimulation. Rowlett JK; Mattingly BA; Bardo MT Synapse; 1993 Jun; 14(2):160-8. PubMed ID: 8332946 [TBL] [Abstract][Full Text] [Related]
8. Changes in the sensitivity to apomorphine of dopamine receptors modulating dopamine and acetylcholine release after chronic treatment with bromocriptine or haloperidol. Cubeddu LX; Hoffmann IS; James MK; Niedzwiecki DM J Pharmacol Exp Ther; 1983 Sep; 226(3):680-5. PubMed ID: 6887008 [TBL] [Abstract][Full Text] [Related]
9. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning. Feifel D; Priebe K; Johnstone-Miller E; Morgan CJ Psychopharmacology (Berl); 2002 Jul; 162(2):138-46. PubMed ID: 12110991 [TBL] [Abstract][Full Text] [Related]
10. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Przedborski S; Levivier M; Raftopoulos C; Naini AB; Hildebrand J Mov Disord; 1995 Jan; 10(1):28-36. PubMed ID: 7885353 [TBL] [Abstract][Full Text] [Related]
11. Withdrawal from continuous or intermittent cocaine administration: changes in D2 receptor function. King GR; Ellinwood EH; Silvia C; Joyner CM; Xue Z; Caron MG; Lee TH J Pharmacol Exp Ther; 1994 May; 269(2):743-9. PubMed ID: 8182540 [TBL] [Abstract][Full Text] [Related]
12. Changes in sensitivity of release modulating dopamine autoreceptors after chronic treatment with haloperidol. Nowak JZ; Arbilla S; Galzin AM; Langer SZ J Pharmacol Exp Ther; 1983 Aug; 226(2):558-64. PubMed ID: 6875865 [TBL] [Abstract][Full Text] [Related]
13. Heterogeneous rotational responsiveness in 6-hydroxydopamine-denervated rats: pharmacological and neurochemical characterization. Liebman JM; Gerber R; Hall NR; Altar CA Psychopharmacology (Berl); 1988; 96(4):477-83. PubMed ID: 3149769 [TBL] [Abstract][Full Text] [Related]
14. Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels. Themann C; Alvarez Fischer D; Gross S; Westermann R; Weihe E; Kuschinsky K; Schäfer H; Ferger B Naunyn Schmiedebergs Arch Pharmacol; 2002 Jan; 365(1):22-8. PubMed ID: 11862330 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. Yuan H; Sarre S; Ebinger G; Michotte Y Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701 [TBL] [Abstract][Full Text] [Related]
16. Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. Wolf ME; White FJ; Nassar R; Brooderson RJ; Khansa MR J Pharmacol Exp Ther; 1993 Jan; 264(1):249-55. PubMed ID: 8093727 [TBL] [Abstract][Full Text] [Related]
17. Development of tolerance to the antihypertensive effects of highly selective adenosine A2a agonists upon chronic administration. Webb RL; Sills MA; Chovan JP; Peppard JV; Francis JE J Pharmacol Exp Ther; 1993 Oct; 267(1):287-95. PubMed ID: 8229754 [TBL] [Abstract][Full Text] [Related]
18. Presynaptic inhibition of nigrostriatal dopamine release in the mouse: lack of cross tolerance between apomorphine, GBL and CGS 10746B. Wood PL; Altar CA; Kim HS Life Sci; 1988; 42(16):1503-6. PubMed ID: 3352463 [TBL] [Abstract][Full Text] [Related]
19. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice. Beland FA Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702 [TBL] [Abstract][Full Text] [Related]
20. Effect of chronic m-CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat. Fone KC; Austin RH; Topham IA; Kennett GA; Punhani T Br J Pharmacol; 1998 Apr; 123(8):1707-15. PubMed ID: 9605579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]